Ozempic / Semaglutide Marketing & Claimant Acquisition

The litigation landscape

Litigation against Novo Nordisk centers on claims that semaglutide — the active ingredient in Ozempic and related branded products — caused or contributed to gastroparesis (severely delayed gastric emptying), ileus (paralysis of the intestines), and bowel obstruction in patients who used the drug. These are not minor side effects; they are debilitating, often requiring emergency intervention or inpatient hospitalization, and plaintiffs allege the risks were not adequately communicated at the time of prescribing.

Intake is currently open, and plaintiff firms are actively building dockets. The injury set is medically distinct and documentable — hospital records, imaging, and gastroenterology notes create a paper trail that supports case evaluation. With Novo Nordisk as the named manufacturer and a drug that remains widely prescribed and culturally prominent, the litigation has the profile characteristics that sustain a long-running, high-volume acquisition campaign.

Who a campaign targets

• Core target audience: Individuals who used a semaglutide-based medication (including Ozempic) for three or more months and received a diagnosis of gastroparesis or ileus, particularly those who required hospitalization as a result of their condition.
• Strong claimant profile: Documented semaglutide use of three-plus months, a confirmed diagnosis of gastroparesis or ileus, and at least one hospitalization directly tied to the gastrointestinal injury — this combination produces the records-supported case profile firms are prioritizing.
• Borderline / secondary audience: Users with shorter durations of use (under three months) or whose gastrointestinal event resulted in an ER visit but not a full inpatient admission may still warrant intake review depending on the firm's docket strategy and the severity of the documented injury.
• Bowel obstruction cases: Individuals diagnosed with bowel obstruction in the context of semaglutide use should be captured in intake flows for firm-level evaluation, as this injury falls within the associated harm set for this litigation.

How MTAA runs Ozempic / Semaglutide campaigns

Semaglutide's brand recognition is a creative asset. Unlike many mass torts where the product name requires explanation, Ozempic is one of the most talked-about medications in recent memory — which means ad creative can lead with the drug name and immediately achieve recognition without education overhead. The creative angle pivots quickly from recognition to consequence: users who developed serious stomach or intestinal problems, needed hospitalization, or were diagnosed with gastroparesis or a bowel condition after taking the medication. That pivot — from a drug they know to an injury they lived — is where engagement happens on Meta placements.

Audience targeting layers naturally here. We build around age and demographic signals consistent with the GLP-1 prescribing population, layered with interest and behavioral signals tied to digestive health conditions and medication management. Intake qualification is structured to surface the hospitalization and diagnosis data points early in the funnel, so firms receive leads pre-screened against the strong-case criteria before a case manager touches them. For firms running high volume, we can build separate creative tracks for the core hospitalized gastroparesis audience and a softer track for the borderline ER-visit population, keeping cost-per-qualified-lead efficient across both segments.